Early ASCO winners? Roche and Pfizer, and to a lesser extent, BMS

The curtain is up on the first act of the annual cancer drug lollapalooza at ASCO. The first round of abstracts spotlights a series of early winners--including Roche ($RHHBY)--and at least one big loser: Puma Biotechnology ($PBYI). Bristol-Myers Squibb ($BMY) delivered some mixed results, while Pfizer ($PFE) was able to tout early data on a lung cancer treatment for patients who've failed on its targeted med Xalkori. More from FierceBiotech